Guse Kyle 4

What Happened

• Kyle Guse, a director of Plus Therapeutics (PSTV), was granted two restricted stock unit (RSU) awards on May 14, 2026 — 3,686 RSUs each, for a total of 7,372 RSUs. The awards are recorded at $0.00 per share (award/grant, Form 4 code A) because they are compensation-based derivative securities, not open-market purchases.

Key Details

• Transaction date: May 14, 2026; Form 4 filed May 18, 2026 (timely filing).
• Award size and price: Two grants of 3,686 RSUs (total 7,372 RSUs) at $0.00 per share (derivative RSUs).
• Amount owned after transaction: Not disclosed in the Form 4 provided.
• Footnote F1: Each RSU is a contingent right to one share; vesting ratably over four quarters, with 1/4 vesting on July 1, 2026 and the remainder vesting quarterly thereafter.
• Footnote F2: Describes a monthly 12-month vesting schedule for options (full vest at the 2027 annual meeting); no option exercise/option grant is reported in these transactions.
• Transaction code: A = Award/Grant (derivative RSUs).

Context

• RSUs are not immediate shares — they convert to common stock only as they vest, so these grants do not represent an immediate purchase or sale. Grants are common as compensation for directors and executives and should be viewed as part of pay arrangements rather than a direct trading signal.